SYSMEX CORP.UNSP.ADR 1/2 (0YX0) - Total Liabilities
Based on the latest financial reports, SYSMEX CORP.UNSP.ADR 1/2 (0YX0) has total liabilities worth €186.25 Billion EUR (≈ $217.75 Billion USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 0YX0 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
SYSMEX CORP.UNSP.ADR 1/2 - Total Liabilities Trend (2022–2025)
This chart illustrates how SYSMEX CORP.UNSP.ADR 1/2's total liabilities have evolved over time, based on quarterly financial data. See SYSMEX CORP.UNSP.ADR 1/2 free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
SYSMEX CORP.UNSP.ADR 1/2 Competitors by Total Liabilities
The table below lists competitors of SYSMEX CORP.UNSP.ADR 1/2 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lily Group Co Ltd
SHG:603823
|
China | CN¥783.77 Million |
|
United Internet AG NA
XETRA:UTDI
|
Germany | €6.67 Billion |
|
RXO Inc.
NYSE:RXO
|
USA | $1.76 Billion |
|
Guoyuan Securities Co Ltd
SHE:000728
|
China | CN¥147.32 Billion |
|
New Hope Liuhe Co Ltd
SHE:000876
|
China | CN¥82.46 Billion |
|
Scholar Rock Holding Corp
NASDAQ:SRRK
|
USA | $166.72 Million |
|
Resideo Technologies Inc
NYSE:REZI
|
USA | $5.29 Billion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs13.57 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down SYSMEX CORP.UNSP.ADR 1/2's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is SYSMEX CORP.UNSP.ADR 1/2 worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SYSMEX CORP.UNSP.ADR 1/2's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SYSMEX CORP.UNSP.ADR 1/2 (2022–2025)
The table below shows the annual total liabilities of SYSMEX CORP.UNSP.ADR 1/2 from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | €200.73 Billion ≈ $234.68 Billion |
+7.91% |
| 2024-03-31 | €186.02 Billion ≈ $217.48 Billion |
+30.34% |
| 2023-03-31 | €142.72 Billion ≈ $166.85 Billion |
+5.99% |
| 2022-03-31 | €134.65 Billion ≈ $157.42 Billion |
-- |
About SYSMEX CORP.UNSP.ADR 1/2
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematol… Read more